Navigation Links
APL novel method accurately predicts disease outbreaks
Date:3/22/2013

A team of scientists from the Johns Hopkins University Applied Physics Laboratory (APL) has developed a novel method to accurately predict dengue fever outbreaks several weeks before they occur.

The new method, known as PRedicting Infectious Disease Scalable Model (PRISM), extracts relationships between clinical, meteorological, climatic and socio-political data in Peru and in the Philippines. It can be used in any geographical region and extended to other environmentally influenced infections affecting public health and military forces worldwide.

PRISM is aimed at helping decision-makers and planners assess the future risk of a disease occurring in a specific geographic area at a specific time. Developed by APL's Anna Buczak and a team of researchers for the Department of Defense (DoD), PRISM predicts the severity of a given disease at a specific time and place with quantifiable accuracy, using original analytical and statistical methods. "By predicting disease outbreaks when no disease is present, PRISM has the potential to save lives by allowing early public health intervention and decreasing the impact of an outbreak," says Sheri Lewis, APL's Global Disease Surveillance Program Manager. DoD is currently evaluating PRISM for use in mitigating the effects of infectious disease in various operational settings.

PRISM's distinctive prediction method utilizes Fuzzy Association Rule Mining (FARM) to extract relationships between multiple variables in a data set. These relationships form rules, and when the best set of rules is automatically chosen, a classifier is formed. The classifier is then used to predict future incidence of the disease in this case dengue fever, the second most common mosquito-borne disease, which puts more than one-third of the world's population at risk.

"PRISM is designed to help public health leaders make informed decisions, mitigate threats and more effectively protect their populations," says Lewis. "Ideally, decision-makers want to learn about a disease outbreak before it spreads and PRISM will provide them with highly accurate information to protect our military forces deployed in at-risk areas."

While PRISM's pilot predictive analysis was the study of dengue fever in Peru, APL scientists have extended the method to predicting dengue in the Philippines and are working to fine-tune the model and expand its capabilities to include other infectious diseases. "Dengue was the starting point for our work because the data were readily available, but eventually we want to apply the methodology to other diseases, such as malaria and influenza," says Lewis.

Once fully operational, PRISM will aid in the earliest possible detection of illness within a community by complementing electronic disease surveillance systems such as the APL-developed Electronic Surveillance System for the Early Notification of Community-based Epidemics (ESSENCE) and the Suite of Automated Global Electronic bioSurveillance (SAGES).

ESSENCE collects, processes and analyzes non-traditional data sources to identify disease activity in a community, allowing data to be queried, analyzed and visualized by the end user. SAGES is a collection of freely available software, including open source versions of ESSENCE, for electronic surveillance in countries with little funding for public health initiatives. SAGES can be used alone or with existing surveillance applications providing governments with the flexibility to develop inexpensive and customized systems to collect and track information about the spread of diseases.


'/>"/>

Contact: Gina Ellrich
Gina.Ellrich@jhuapl.edu
240-228-7796
Johns Hopkins University
Source:Eurekalert

Related biology news :

1. Novel insights into the evolution of protein networks
2. UMass Amherst researchers reveal mechanism of novel biological electron transfer
3. Novel treatment approach for bladder pain using a herpes simplex virus vector reported
4. Scientists discover novel chemical that controls cell behavior
5. BGI Tech develops novel Ultra-Deep de novo assembly solution for heterozygous genomes
6. Novel storage mechanism allows command, control of memory
7. Brown unveils novel wireless brain sensor
8. Novel combination therapy shuts down escape route, killing glioblastoma tumor cells
9. Novel coronavirus well-adapted to humans, susceptible to immunotherapy
10. Novel test streamlines testing for Huntington Disease
11. New tool for mining bacterial genome for novel drugs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/3/2016)... , June 3, 2016 ... von Nepal hat ... Lieferung hochsicherer geprägter Kennzeichen, einschließlich Personalisierung, Registrierung ... in der Produktion und Implementierung von Identitätsmanagementlösungen. ... Ausschreibung im Januar teilgenommen, aber Decatur wurde ...
(Date:6/1/2016)... NEW YORK , June 1, 2016 ... Biometric Technology in Election Administration and Criminal Identification to ... According to a recently released TechSci Research report, " ... Sector, By Region, Competition Forecast and Opportunities, 2011 - ... $ 24.8 billion by 2021, on account of growing ...
(Date:5/12/2016)... May 12, 2016 WearablesResearch.com , a ... the overview results from the Q1 wave of its ... wave was consumers, receptivity to a program where they ... a health insurance company. "We were surprised ... says Michael LaColla , CEO of Troubadour Research, ...
Breaking Biology News(10 mins):
(Date:6/23/2016)... , June 23, 2016   EpiBiome , ... secured $1 million in debt financing from Silicon Valley ... up automation and to advance its drug development efforts, ... new facility. "SVB has been an incredible ... the services a traditional bank would provide," said Dr. ...
(Date:6/23/2016)... ... June 23, 2016 , ... STACS DNA Inc., the sample tracking software company, ... Crime Laboratory, has joined STACS DNA as a Field Application Specialist. , “I ... President and COO of STACS DNA. “In further expanding our capacity as a scientific ...
(Date:6/23/2016)... 2016 Apellis Pharmaceuticals, Inc. today announced ... of its complement C3 inhibitor, APL-2. The trials ... dose studies designed to assess the safety, tolerability, ... in healthy adult volunteers. Forty subjects ... single dose (ranging from 45 to 1,440mg) or ...
(Date:6/23/2016)... 23, 2016 Andrew ... http://doi.org/10.17925/OHR.2016.12.01.22 Published recently in ... journal from touchONCOLOGY, Andrew D Zelenetz , ... cancer care is placing an increasing burden on ... biologic therapies. With the patents on many biologics ...
Breaking Biology Technology: